Prior to his appointment as CEO of Synaptive Medical in October 2017, Peter Wehrly was chairman of the Board of Directors and an advisor to the company. He is the former group president of developed markets at Covidien, the manufacturer of medical devices with sales of over $10.7 billion (2014). Peter held profit and loss responsibility for the marketing and sale of products to all developed markets outside the U.S. between 2013 and 2015. He departed following the $42-billion sale of Covidien to Medtronic Inc. in 2015. Prior to this role, Peter was the president of Respiratory and Monitoring Solutions, and was responsible for Covidien’s Japanese, Australia-New Zealand and Canadian businesses. He has also held leadership positions at Medingo Youqneam, an Israel-based team that developed a novel, low-cost, patient benefit-rich insulin pump for diabetic patients that was ultimately sold to Roche, and Medtronic’s Spinal and Biologics business. He started his career with DePuy, a Johnson & Johnson company.